l e t t e r S Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. With ~170 million individuals infected and current interferon-based treatment having toxic side effects and marginal efficacy, more effective antivirals are crucially needed 1 . Although HCV protease inhibitors were just approved by the US Food and Drug Administration (FDA), optimal HCV therapy, analogous to HIV therapy, will probably require a combination of antivirals targeting multiple aspects of the viral lifecycle. Viral entry represents a potential multifaceted target for antiviral intervention; however, to date, FDA-approved inhibitors of HCV cell entry are unavailable. Here we show that the cellular Niemann-Pick C1-like 1 (NPC1L1) cholesterol uptake receptor is an HCV entry factor amendable to therapeutic intervention. Specifically, NPC1L1 expression is necessary for HCV infection, as silencing or antibody-mediated blocking of NPC1L1 impairs cell culture-derived HCV (HCVcc) infection initiation. In addition, the clinically available FDA-approved NPC1L1 antagonist ezetimibe 2,3 potently blocks HCV uptake in vitro via a virion cholesterol-dependent step before virion-cell membrane fusion. Moreover, ezetimibe inhibits infection by all major HCV genotypes in vitro and in vivo delays the establishment of HCV genotype 1b infection in mice with human liver grafts. Thus, we have not only identified NPC1L1 as an HCV cell entry factor but also discovered a new antiviral target and potential therapeutic agent.
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HCV is thought to enter cells via receptor-mediated endocytosis beginning with interaction of the viral particle with a series of cell surface receptors, including the tetraspanin CD81 protein 4 , scavenger receptor class B member I (SR-BI, also known as SCARB1) 5 and the tight-junction proteins claudin-1 (CLDN1) 6 and occludin (OCLN) 7, 8 , followed by clathrin-mediated endocytosis and fusion between the virion envelope and the endosomal membrane 9, 10 . Although the specifics of each interaction are not fully understood, it is now recognized that multiple cellular factors, as well as many components of the viral particle, not just the viral glycoproteins, participate in the entry process. For example, the HCVcc particle is associated with cellular lipoproteins (for example, low-density lipoprotein and verylow-density lipoprotein) 11, 12 and is enriched in cholesterol 13 , the latter of which has been shown to be necessary for HCV cell entry 13, 14 . Apart from the likely function of cholesterol in viral membrane stabilization and organization, the dependence of HCV infectivity on cholesterol led us to reason that other cholesterol-uptake receptors (apart from SR-BI and LDLR), such as NPC1L1, might also have a role in HCV cell entry.
NPC1L1, a 13-transmembrane-domain cell surface cholesterolsensing receptor ( Fig. 1a ) expressed on the apical surface of intestinal enterocytes and human hepatocytes, including Huh7 cells ( Supplementary Fig. 1 ), is responsible for cellular cholesterol absorption and whole-body cholesterol homeostasis 15, 16 . Similar to what has been observed for other HCV entry factors 8 , we observed downregulation of NPC1L1 in HCVcc-infected Huh7 cultures. Specifically, as early as day 4 after infection NPC1L1 protein levels were markedly reduced and remained downregulated until the end of the experiment at day 12 after infection ( Fig. 1b) . Having observed a correlation between NPC1L1 expression and HCV infection, we next determined whether NPC1L1 expression levels affect HCV infection by transfecting Huh7 cells with siRNAs targeting NPC1L1 or the known HCV entry factors CD81 or SR-BI. Compared to cells transfected with an irrelevant control siRNA, CD81-, SR-BI-and NPC1L1-silenced cells were significantly less susceptible to HCVcc infection (Fig. 1c) . The inhibition was HCV specific, as silencing of these proteins had no effect on vesicular stomatitis virus G proteinpseudotyped particle (VSVGpp) infection ( Supplementary Fig. 2a ). Inhibition of HCV also correlated with a reduction in NPC1L1 mRNA and protein and was NPC1L1 specific and not the result of off-target effects ( Fig. 1d,e, Supplementary Figs. 3 and 4a,b) . Although protein amounts were only marginally lowered by siRNA knockdown, the effect on HCV was considerable, highlighting the sensitivity of HCV to small changes in NPC1L1 levels. Notably, SR-BI mRNA expression has been shown to be reduced by NPC1L1 knockdown in nonhepatic cells 17 and SR-BI is an HCV entry factor 5 , but we found that SR-BI expression was not adversely affected by NPC1L1 silencing in Huh7 cells ( Supplementary Fig. 4c,d) . Finally, NPC1L1 silencing had no effect on HCV subgenomic RNA replication, full-length infectious HCVcc RNA replication or secretion of de novo HCVcc (Supplementary Fig. 5 ).
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor l e t t e r S Because siRNA-mediated knockdown of NPC1L1 suggested that HCV infection is inhibited at a step before RNA replication or secretion, we next assessed whether HCV infection was susceptible to inhibition by antibody-mediated blocking of cell surface NPC1L1. Compared to cells treated with irrelevant IgG control antibodies, HCVcc infection, as measured by intracellular HCV RNA levels, was significantly reduced in cells treated with an antibody specific for the known HCV cell entry factor CD81 ( Fig. 1f) . When we incubated cells with an NPC1L1-specific antibody, HCVcc infection was similarly reduced (Fig. 1f) , and the inhibition was HCV specific, as antibody-mediated blocking had no effect on VSVGpp entry ( Supplementary Fig. 2b,c) . To determine the NPC1L1 domains necessary for HCV entry, we treated cells with antibodies targeting each of the three large extracellular loops (LELs) of NPC1L1 and observed that HCV infection was reduced only when NPC1L1 LEL1, but not LEL2 or LEL3, was blocked ( Fig. 1g) . Thus, NPC1L1 silencing and antibody-mediated blocking of NPC1L1 LEL1 reduced HCV infection as effectively as targeting other known HCV cell entry factors.
Ezetimibe is a 2-azetidinone-class drug that has been approved by the FDA as a cholesterol-lowering medication 18 . As ezetimibe has been shown to be a direct inhibitor of NPC1L1 internalization 19, 20 , we next used this high-affinity, specific pharmacological agent as an alternate means of targeting NPC1L1 before, during or after viral inoculation while additionally evaluating its anti-HCV potential. Specifically, we performed HCVcc foci-reduction assays and quantified foci (that is, clusters of ≥5 HCV E2-positive cells) after ezetimibe treatment. Ezetimibe reduced HCVcc foci formation in a dose-dependent manner when present before infection and then removed ( Fig. 2a ) or only during virus inoculation ( Fig. 2b) . However, when we added ezetimibe to cells after inoculation ( Fig. 2c) , the initiation of HCV-positive foci was unaffected, as would be expected for a viral entry inhibitor. Notably, the highest dose of ezetimibe (25 µM) reduced the size of the HCV-positive foci observed from the typical ≥5 HCV E2-positive cells to only 1-3 HCV E2-positive cells per focus, which accounts for the lower number of foci with ≥5 HCV E2-positive cells being counted in those cultures, suggesting that NPC1L1 may also affect HCV cell-to-cell spread (data not shown). Dose-responsive, time-of-addition-dependent inhibition of HCV infection was also evident when HCV RNA levels were measured ( Supplementary Fig. 6 ). We additionally observed ezetimibe sensitivity across a panel of HCVcc intergenotypic clones containing the structural regions of diverse HCV genotypes (1 -7) 21 (Fig. 2d) . Finally, because NPC1L1 and SR-BI are both involved in cellular cholesterol uptake and SR-BI has been reported to be a rate-limiting HCV cell entry factor 22 , we overexpressed SR-BI before ezetimibe treatment and found that this overexpression did not overcome the dependence of HCV entry on NPC1L1 ( Supplementary Fig. 7) . Likewise, we confirmed that the potent antiviral effect of ezetimibe was not due to drug-mediated cytotoxicity ( Supplementary Figs. 2d,e and 8a) , changes in cell proliferation ( Supplementary Fig. 8b) , reduced expression of the other known HCV cell surface receptors ( Supplementary Fig. 8c-g) , inhibition of HCV RNA replication (Supplementary Fig. 9a -c) or inhibition of virus secretion (Supplementary Fig. 9d ). Hence, the data support the conclusion that direct pharmacological inhibition of NPC1L1 reduces HCV infection by directly inhibiting viral cell entry.
We next assessed whether ezetimibe inhibits HCVcc binding or a post-binding step by examining cell-associated HCV RNA and protein expression from internalized RNA in vehicle-and ezetimibetreated HCVcc-infected cultures. At 10 h after infection, a time before detectable HCV RNA replication occurs ( Supplementary Fig. 10 ), ezetimibe did not affect cell-bound HCV RNA levels ( Fig. 2e) . In contrast, at later time points, HCV RNA levels ( Fig. 2e) and de novo NS5A protein expression ( Fig. 2f,g) were reduced in ezetimibe-treated cultures, suggesting HCV can efficiently bind ezetimibe-treated cells, but a post-binding step is prevented. To further test this hypothesis and determine when during the entry process NPC1L1 functions, we assessed the ability of ezetimibe to block HCVcc infection when added at various times after virus binding at 4 °C. Ezetimibe retained inhibitory activity after temperature shift to 37 °C for up to 5 h (halfmaximal inhibition at 4 h), confirming that NPC1L1 functions after binding, probably late in viral entry ( Fig. 2h) .
To determine whether ezetimibe acts before fusion, we developed a fluorescence-based HCVcc fusion assay. Specifically, we labeled HCVcc with the hydrophobic fluorophore DiD 23 , which incorporates into biological membranes and, at high concentrations, is self-quenching. Upon fusion of viral and target membranes, the DiD fluorophores diffuse away from each other, causing dequenching and allowing for the progression or inhibition of fusion to be measured in real time (Supplementary Fig. 11 ). Compared to NH 4 Cl, an inhibitor of endosomal acidification 9 , ezetimibe more potently inhibited HCVcc DiD fusion, such that by 12 h after binding we measured only ~10% HCVcc DiD dequenching in ezetimibetreated cultures as compared to vehicle-treated controls (Fig. 2i) . Analogously, antibody-mediated inhibition of both CD81 and NPC1L1 also reduced HCVcc DiD fusion (Fig. 2j) , indicating that the inhibition observed in ezetimibe-treated wells (Fig. 2i) was not drug specific. We also observed similar results using HCVcc DiD alternatively purified by iodixanol density gradient centrifugation ( Supplementary Fig. 12a,b) .
As not all viral membrane-incorporated DiD is self-quenched, DiD can also serve as a fluorescent tag to monitor virions during cell entry 24 . Taking advantage of this, we performed fluorescence microscopy analysis of HCVcc DiD -infected cultures and noted that although we observed little DiD on the surface of vehicle-treated cells, indicative of successful viral entry and fusion, we observed markedly more DiD on the surface of ezetimibe-treated cells (Supplementary Fig. 12c,d) . Together with the DiD-fusion data, this indicates that inhibition of NPC1L1 prevents HCVcc cell entry at or before virion-host cell fusion.
Given that antibody-mediated blocking of only NPC1L1 LEL1 (Fig. 1g ) reduced HCVcc infection, LEL1 has been shown to bind cholesterol 20, 25 and infectious HCV particles are enriched in cholesterol 13, 26 , we next investigated whether the dependence of HCV cell entry on NPC1L1 might be related to the cholesterol contained within the HCV virions 13 . To address this hypothesis, we used viruses containing the E1/E2 glycoproteins derived from the HCV JFH-1 consensus clone but that differ in their virion-associated cholesterol content and assessed their relative dependence on NPC1L1. Specifically, we found that lentivirus particles pseudotyped with the JFH-1 HCV glycoproteins (HCVpp) contained 94% less cholesterol than the authentic JFH-1 HCVcc particles (HCVcc WT ). In contrast, cell culture-adapted HCVcc G451R produced from a JFH-1 viral clone with a G451R point mutation in the viral E2 glycoprotein (HCVcc G451R ) contained ~50% more cholesterol than HCVcc WT (Fig. 3a) . These cholesterol profiles are consistent with the fact that HCVpp is produced from 293T embryonal kidney cells, which do not produce cholesterol-associated lipoproteins 27 , and are therefore compositionally distinct from HCVcc, whereas HCVcc G451R has a narrower density range with a higher average mean density than the original JFH-1-derived HCVcc WT (ref. 28) . As expected, when CD81 was silenced, both HCVpp (Fig. 3b) and HCVcc G451R (Fig. 3c ) cell entry was reduced; however, when NPC1L1 was silenced or inhibited by ezetimibe, the cholesterol-scarce HCVpp showed NPC1L1independent cell entry and insensitivity to ezetimibe inhibition (Fig. 3b,d) . In contrast, the cholesterol-abundant HCVcc G451R showed enhanced NPC1L1-dependent cell entry and hypersensitivity to ezetimibe-mediated inhibition (Fig. 3c,e ). Together, these data reveal a correlation between the amount of virion-associated cholesterol and dependence on NPC1L1 for HCV cell entry. Finally, to assess the involvement of NPC1L1 in HCV cell entry in vivo, we evaluated the ability of ezetimibe to inhibit infection of a genotype 1 clinical isolate in a hepatic xenorepopulation model of acute HCV infection 29 . Specifically, we repopulated urokinase-type plasminogen activator-severe combined immunodeficiency (uPA-SCID) mice with human hepatocytes and treated them via oral gavage with ezetimibe (10 mg per kg body weight per day) or diluent alone for a total of 3 weeks, with treatment beginning 2 weeks, 1 week or 2 d before challenge with HCV genotype 1b positive serum (Fig. 4a) .
Ezetimibe treatment delayed the establishment of HCV infection in mice pretreated for 2 weeks before infection ( Fig. 4b, P = 0.0192) , confirming the ability of this drug to inhibit HCV infection in vivo. However, when mice were pretreated for only 1 week before infection, ezetimibe was less effective at delaying infection (P = 0.062), and it was completely ineffective when treatment was initiated only 2 d before challenge or after infection had been established (data not shown). Specifically, 100% of the nine control diluent-treated mice were serum positive for HCV 1 week after challenge, whereas 71% (five out of seven) and 43% (three out of seven) of mice treated with ezetimibe for 2 weeks and 1 week before infection were HCV negative, respectively (Fig. 4b,c) . Although the majority of ezetimibetreated mice eventually became HCV positive, of the five mice in the 2-week ezetimibe pretreatment group that were HCV negative at week 1, two were completely protected, remaining HCV negative at weeks 2 and 3 after infection (and one mouse died during gavage) ( Supplementary Fig. 13 ). Thus, similar to what was recently reported for another potential HCV entry inhibitor, erlotinib 30 , ezetimibe was able to delay initial infection in vivo. Notably, since NPC1L1 is highly expressed on the apical surface of intestinal enterocytes 15,16 , a considerable amount of orally administered ezetimibe initially binds to these cells following oral administration 31 . Thus it is plausible that development of alternate non-oral delivery or drug-targeting methods Group 2: Untreated Ezetimibe npg might improve transport of ezetimibe to hepatocytes and increase its anti-HCV efficacy. Nevertheless, our finding that ezetimibe can delay the establishment of HCV genotype 1 infection in mice confirms the involvement of NPC1L1 in HCV infection in vivo and highlights the therapeutic potential of further pursuing the refinement or development of anti-NPC1L1 therapies 32 for the treatment of HCV.
Here we have shown that NPC1L1 is an HCV cell entry factor that functions after binding, at or before fusion. These findings, together with the facts that NPC1L1 is a cellular cholesterol receptor, the HCV particle is enriched in cholesterol, and relative dependence on NPC1L1 is correlated with HCV particle cholesterol levels, support and expand upon previous reports suggesting that virion cholesterol is involved in HCV cell entry 13, 14, 26 . Whether NPC1L1 directly interacts with HCV or indirectly participates in HCV entry by removing virion-associated cholesterol to perhaps reveal protected viral glycoprotein binding sites or confer a required conformational change remains to be determined. Lastly, as NPC1L1 is expressed only on human and primate hepatocytes 33, 34 , this discovery additionally highlights NPC1L1 as a potential HCV tropism determinant, which may facilitate the future development of a small-animal model of HCV infection.
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HCVcc. Plasmids containing the full-length HCV JFH-1 genome (pJFH1) 36 , full-length HCV JFH-1 genome with a G451R mutation in the E2 glycoprotein (pJFH-1 G451R ) 37 and the eight intergenotypic clones (described in ref. 21) were XbaI linearized and transcribed using MEGAscript T7 (Ambion), and 10 µg in vitro-transcribed RNA was electroporated (BioRad) into Huh7 cells 38 . We generated HCVcc viral stocks by infecting naive Huh7 cells at an MOI of 0.01 FFU per cell with medium from Huh7 cells electroporated with in vitrotranscribed RNA from pJFH-1-based vectors, as previously described 38 .
Treatments and analysis. Huh7 cultures were established as previously described 38 . We performed RNA silencing experiments by reverse transfection (Lipofectamine RNAiMAX, Invitrogen) of siRNAs into Huh7 cells. Transfected cells were infected with equal titers of HCVpp or VSVGpp or HCVcc at an MOI of 0.05 FFU per cell) at the indicated times after transfection ( Fig. 1c-e ). For antibody experiments, we treated cells with 36 µg ml −1 of antibody before and during infection with HCVcc at an MOI of 0.05 FFU per cell. For ezetimibe inhibition experiments, cells were vehicle-treated or treated with increasing concentrations of ezetimibe (Sequoia Research Products) before infection, during the time of virus inoculation and/or after virus inoculation with HCVcc at an MOI of 0.1-1.0 FFU per cell. The ezetimibe concentrations of 3.125-30 µM (that is, 1.5-12.28 µg per ml culture medium) used in this study are consistent with previously published reports 19, 20, 39 and are additionally in line with patient daily intake concentrations of 10 mg d −1 (that is, 2.0-3.3 µg per ml of serum). For RT-qPCR analysis, we isolated total cellular RNA from triplicate culture wells after infection or transfection. For HCV E2-positive foci analysis, we fixed infected cells with 4% (wt/vol) paraformaldehyde 72 h after infection, and immunocytochemical staining for HCV E2 was performed. See Supplementary Methods for further details.
HCV infection in chimeric mice. All mouse studies were conducted with protocols approved by the Ethics Review Committee for Animal Experimentation of the Graduate School of Biomedical Sciences, Hiroshima University. Male uPA-SCID mice transplanted with human hepatocytes (BD Biosciences 35 ) were purchased from PhenixBio 40 . Mice were treated daily with 10 mg per kg body weight ezetimibe via oral gavage of a 0.02 mg ml −1 solution of ezetimibe resuspended in corn oil (100 µl 20g −1 ) for a total of 3 weeks, with treatment initiation beginning 2 weeks, 1 week or 2 d before infection 16 . Control mice were treated via oral gavage with corn oil alone (100 µl per 20 g body weight). A total of four to seven mice were included in each group. On day 0, we intravenously inoculated mice with serum from HCV-infected humans containing 1.0 × 10 5 copies of HCV genotype 1b. Mouse serum samples were obtained for HCV RNA or human albumin determination by RT-qPCR and Alb-II Kit (Eiken Chemical), respectively.
Statistical analyses. Data are presented as the means ± s.d. We determined significant differences by one-way ANOVA followed by Tukey's post-hoc t test (GraphPad Prism software). To compare categorical variables we used a twotailed Fisher's exact test (SPSS). In all cases, a P value <0.05 was considered statistically significant.
Additional methods. Detailed methodology is described in the Supplementary Methods.
